EUVIMEDEUVIMED entdecken
Leitlinie

Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1

Lyudmila Bazhenova iD, Nofisat Ismaila iD, Greg Durm iD, Janet Freeman-Daily iD, Hidehito Horinouchi iD, Gary R MacVicar iD, Deebya Raj Mishra iD, Bruna Pellini iD, Erin L Schenk iD, Navneet Singh iD, Natasha B Leighl iD

Journal of Clinical Oncology · 20.06.2026 · 44 (18)

DOI: 10.1200/jco-26-00842 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.06.2026. Verfasst von Lyudmila Bazhenova und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of California San Diego Moores Cancer Center, San Diego, CA. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Practice Guidelines as Topic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 , online only). Updates are published regularly and can be found at https://ascopubs.org/nsclc-non-da-living-guideline .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungPractice Guidelines as TopicHumansNeoplasm Staging

Autor:innen und Institutionen

  • University of California San Diego Moores Cancer Center, San Diego, CA.
  • American Society of Clinical Oncology (ASCO), Alexandria, VA.
  • Indiana University Health, Indianapolis, IN.
  • The ROS1ders, Seattle, WA.
  • National Cancer Center Hospital, Tokyo, Japan.
  • Illinois CancerCare, Peoria, IL.

ORCID-Profile: Lyudmila Bazhenova, Nofisat Ismaila, Greg Durm, Janet Freeman-Daily, Hidehito Horinouchi, Gary R MacVicar, Deebya Raj Mishra, Bruna Pellini, Erin L Schenk, Navneet Singh, Natasha B Leighl

Zitieren

APA

Bazhenova, L., Ismaila, N., Durm, G., Freeman-Daily, J., Horinouchi, H., MacVicar, G. R., Mishra, D. R., Pellini, B., Schenk, E. L., Singh, N., & Leighl, N. B. (2026). Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1. Journal of Clinical Oncology, 44(18). https://doi.org/10.1200/jco-26-00842

Vancouver

Bazhenova L, Ismaila N, Durm G, Freeman-Daily J, Horinouchi H, MacVicar GR, et al. Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1. Journal of Clinical Oncology. 2026;44(18). doi:10.1200/jco-26-00842

BibTeX
@article{Bazhenova2026,
  author = {Bazhenova, Lyudmila and Ismaila, Nofisat and Durm, Greg and Freeman-Daily, Janet and Horinouchi, Hidehito and MacVicar, Gary R and Mishra, Deebya Raj and Pellini, Bruna and Schenk, Erin L and Singh, Navneet and Leighl, Natasha B},
  title = {Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {18},
  doi = {10.1200/jco-26-00842}
}
Kostenlos starten →